TGNA:FRA
Transgene SA
€0.67
arrow_downward
-0.15%(-0.00100) 1D
Okt 15, 10:00:00 PM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa TGNA...
Buksan
€0.67
Mataas
€0.67
Mababa
€0.67
Mkt. cap
192.75M
Avg. na dami
0.00
Dami
0.00
Mataas nang 52-wk
€1.48
Mababa nang 52-wk
€0.60
EPS
-€0.17
Bilang ng mga empleyado
152
Buksan
€0.67
Mataas
€0.67
Mababa
€0.67
Mkt. cap
192.75M
Avg. na dami
0.00
Dami
0.00
Mataas nang 52-wk
€1.48
Mababa nang 52-wk
€0.60
EPS
-€0.17
Bilang ng mga empleyado
152
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Reuters
·
4 oras ang nakalipas
S&P 500 ends higher as traders shift from AI to healthcare
Bloomberg.com
·
4 araw ang nakalipas
S&P 500 Wavers as Earnings Bets Offset Chip Rout: Markets Wrap
MarketWatch
·
1 buwan ang nakalipas
The S&P 500 keeps climbing on days when stocks broadly struggle. Here’s what’s going on.
New York Post
·
3 araw ang nakalipas
Wall Street’s big but narrow rally: 4 in 10 S&P stocks are down this year
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Tungkol sa Transgene SA